DSGN Latest News

Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

globenewswire.com — Mar 9, 2026

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026

Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00

defenseworld.net — Feb 20, 2026

Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) have received an average recommendation of "Moderate Buy" from the five ratings

Design Therapeutics to Participate in Upcoming Investor Conferences

globenewswire.com — Feb 18, 2026

CARLSBAD, Calif. , Feb.

Design Therapeutics (NASDAQ:DSGN) Shares Gap Up – Here’s Why

defenseworld.net — Feb 1, 2026

Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) gapped up prior to trading on Friday.

Brokerages Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $15.00

defenseworld.net — Jan 26, 2026

Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five analysts that are c